Should I buy or sell Merus stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks .

What is Merus' stock price target for 2024?

11 Wall Street research analysts have issued 12 month target prices for Merus' shares. Their MRUS share price targets range from $35.00 to $49.00. On average, they predict the company's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts .

How have MRUS shares performed in 2023?

Merus' stock was trading at $15.47 at the beginning of 2023. Since then, MRUS stock has increased by 54.7% and is now trading at $23.93. View the best growth stocks for 2023 here .

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our MRUS earnings forecast .

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.30. The biotechnology company had revenue of $11.03 million for the quarter, compared to analysts' expectations of $10.96 million. Merus had a negative net margin of 387.00% and a negative trailing twelve-month return on equity of 63.39%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE) , Micron Technology (MU) , OPKO Health (OPK) , Corbus Pharmaceuticals (CRBP) , Exelixis (EXEL) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC) .

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.72%), Federated Hermes Inc. (5.00%), Wellington Management Group LLP (4.74%), RTW Investments LP (3.46%), Braidwell LP (3.29%) and Lynx1 Capital Management LP (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De , Lex Bakker , Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends .

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Merus Stock Price, News & Analysis (NASDAQ:MRUS)

$23.93

-0.83 (-3.35%)

(As of 12/8/2023 ET)

Compare

Today's Range: $23.76
▼
$24.92
50-Day Range: $20.06
▼
$25.13
52-Week Range: $12.44
▼
$27.70

Volume: 344,335 shs
Average Volume: 383,214 shs
Market Capitalization: $1.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.60

Merus MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 86.4% Upside
$44.60 Price Target
Short Interest: Bearish
11.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.14
Based on 8 Articles This Week
Insider Trading: Selling Shares
$14,133 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.61) to ($3.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

803rd out of 932 stocks

Pharmaceutical Preparations Industry

377th out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Merus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.60, Merus has a forecasted upside of 86.4% from its current price of $23.93.
Amount of Analyst Coverage
Merus has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.36% of the outstanding shares of Merus have been sold short.
Short Interest Ratio / Days to Cover
Merus has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Merus has recently increased by 0.31%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Merus does not currently pay a dividend.
Dividend Growth
Merus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MRUS.

1.6

News and Social Media Coverage

News Sentiment
Merus has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Merus this week, compared to 2 articles on an average week.
MarketBeat Follows
9 people have added Merus to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,133.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Merus is held by insiders.
Percentage Held by Institutions
90.68% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Merus are expected to decrease in the coming year, from ($2.61) to ($3.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merus is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merus is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Merus has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRUS Stock News Headlines

December 5, 2023 | finance.yahoo.com

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

December 5, 2023 | americanbankingnews.com

Merus' (MRUS) "Buy" Rating Reaffirmed at Needham & Company LLC

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 4, 2023 | markets.businessinsider.com

Merus: Buy Rating Justified by Clinical Progress and Market Potential

December 4, 2023 | msn.com

Merus falls after updated data for lung cancer therapy

December 3, 2023 | finanznachrichten.de

Merus N.V.: Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

December 3, 2023 | finance.yahoo.com

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

November 29, 2023 | markets.businessinsider.com

Buy Rating on Merus Stock Backed by Strong Clinical Data and Strategic Development Moves

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 28, 2023 | markets.businessinsider.com

Merus’s MCLA-129: Promising Early Results and Strategic Positioning Underpin Buy Rating

November 26, 2023 | finance.yahoo.com

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

November 23, 2023 | finance.yahoo.com

Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

November 7, 2023 | finance.yahoo.com

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet

November 6, 2023 | markets.businessinsider.com

Positive Outlook for Merus: Stability, Promising Pipeline, and Robust Financial Health Reinforce Buy Rating

November 5, 2023 | morningstar.com

Merus NV MRUS

November 4, 2023 | markets.businessinsider.com

Promising Clinical Trials and Future Catalysts Strengthen Buy Rating for Merus

November 2, 2023 | finanznachrichten.de

Merus N.V.: Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

November 2, 2023 | finance.yahoo.com

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

October 23, 2023 | stockhouse.com

Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

October 23, 2023 | finance.yahoo.com

Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

October 19, 2023 | markets.businessinsider.com

Positive Pipeline Developments and Upcoming Trials Bolster Merus Stock: An In-depth Analysis of Berens’ Buy Rating Recommendation

October 17, 2023 | finance.yahoo.com

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

October 16, 2023 | markets.businessinsider.com

Promising Outcomes for Cetuximab and Petosemtamab in HNSCC Treatment: An Analysis of the INTERLINK-1 ESMO Data and Future Prospects

October 15, 2023 | finance.yahoo.com

Merus Announces Business Update Conference Call

October 6, 2023 | finanznachrichten.de

Merus N.V.: Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

October 6, 2023 | finance.yahoo.com

Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

October 5, 2023 | finance.yahoo.com

While Merus (NASDAQ:MRUS) shareholders have made 67% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week

See More Headlines

Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRUS
CUSIP: N/A
CIK: 1651311
Web: www.merus.nl
Phone: (130) 253-8800
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.60
High Stock Price Target: $49.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +86.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-131,190,000.00
Net Margins: -387.00%
Pretax Margin: -381.43%
Return on Equity: -63.39%
Return on Assets: -45.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.29
Quick Ratio: 6.29

Sales & Book Value

Annual Sales: $41.59 million
Price / Sales: 33.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.34 per share
Price / Book: 4.48

Miscellaneous

Outstanding Shares: 57,730,000
Free Float: 55,250,000
Market Cap: $1.38 billion
Optionable: Not Optionable
Beta: 0.82

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Sven Ante Lundberg M.D. (Age 60)
CEO, President & Executive Director
Comp: $953.06k
Mr. Gregory D. Perry (Age 63)
CFO & Principal Financial Officer
Comp: $63.76k
Mr. Peter B. Silverman J.D. (Age 45)
EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Comp: $601.19k
Dr. Hui Liu Ph.D. (Age 56)
Chief Business Officer, Executive VP & Head of Merus U.S.
Comp: $597.7k
Dr. Andrew Joe M.D. (Age 57)
Chief Medical Officer & Senior VP
Comp: $692.74k
Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor
Harry Shuman
Chief Accounting Officer
Mr. Cornelis Adriaan de Kruif Ph.D. (Age 58)
CTO & Executive VP
Comp: $348.73k
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior VP
Ms. Jillian Connell
VP of Investor Relations & Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings or view top-rated stocks.
What is Merus' stock price target for 2024?: 11 Wall Street research analysts have issued 12 month target prices for Merus' shares. Their MRUS share price targets range from $35.00 to $49.00. On average, they predict the company's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts.
How have MRUS shares performed in 2023?: Merus' stock was trading at $15.47 at the beginning of 2023. Since then, MRUS stock has increased by 54.7% and is now trading at $23.93.
View the best growth stocks for 2023 here.
When is Merus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MRUS earnings forecast.
How were Merus' earnings last quarter?: Merus (NASDAQ:MRUS) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.30. The biotechnology company had revenue of $11.03 million for the quarter, compared to analysts' expectations of $10.96 million. Merus had a negative net margin of 387.00% and a negative trailing twelve-month return on equity of 63.39%.
What ETFs hold Merus' stock?: ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC).
When did Merus IPO?: (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?: Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.72%), Federated Hermes Inc. (5.00%), Wellington Management Group LLP (4.74%), RTW Investments LP (3.46%), Braidwell LP (3.29%) and Lynx1 Capital Management LP (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends.
How do I buy shares of Merus?: Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial